Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 in Metastatic Nasopharyngeal Carcinoma
CTR20182470Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in nasopharyngeal carcinoma (NPC), sponsored by Akeso, Inc.. Started Jan 2019; status: completed.
02
Drugs
penpulimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20182470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182470.